Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)

Pharmacokinetics and Drug Metabolism Department, Amgen Research, South San Francisco, California (S.C.H., M.B.T., J.M.L., B.B., R.S., B.M.R.); Hybrid Modality Engineering Department, Amgen Research, Thousand Oaks, California (B.W., K.S.); and Molecular Engineering Department, Amgen Research, Cambridge, Massachusetts (Y.H., X.H.)